QVA149 versus indacaterol, glycopyrronium, placebo, and open-label tiotropium in moderate to severe COPD

Phase 3, randomised, double-blind trial of indacaterol + glycopyrronium, indacaterol, glycopyrronium and tiotropium in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Novartis. Primary endpoints: Trough FEV1 superiority versus indacaterol and glycopyrronium at week 26 and Superiority versus placebo at week 26. Started Jun 2010; status: completed.